Pyoderma gangrenosum
Pyoderma gangrenosum is 'n seldsame, inflammatoriese velsiekte waar pynlike pustules of nodules sere word wat progressief groei. Pyoderma gangrenosum is nie aansteeklik nie. Behandelings kan kortikosteroïede, siklosporien of verskeie monoklonale teenliggaampies insluit. Alhoewel dit mense van enige ouderdom kan raak, raak dit meestal mense in hul 40's en 50's.
☆ In die 2022 Stiftung Warentest-resultate van Duitsland was verbruikerstevredenheid met ModelDerm net effens laer as met betaalde telemedisyne-konsultasies.
Op die been van 'n persoon met ulseratiewe kolitis.
References
Pyoderma gangrenosum is 'n seldsame veltoestand wat pynlike ulkusse met rooi of pers kante veroorsaak. Dit word as 'n inflammatoriese siekte geklassifiseer en is deel van 'n groep genaamd neutrofiele dermatoses. Die oorsaak van pyoderma gangrenosum is kompleks en behels probleme met beide aangebore en aanpasbare immuniteit by mense wat geneties geneig is. Onlangs het navorsers gefokus op die haarfollikel as 'n potensiële beginpunt van die siekte.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is 'n seldsame veltoestand wat uiters pynlike ulkusse veroorsaak. Alhoewel ons nie die oorsaak daarvan ten volle verstaan nie, weet ons dat dit verhoogde aktiwiteit van sekere immuunselle behels. Die behandeling van die siekte is steeds nie maklik nie. Ons het verskeie middels wat die immuunstelsel onderdruk of die aktiwiteit daarvan verander. Hierbenewens fokus ons ook op die behandeling van die wonde en die bestuur van pyn. Kortikosteroïede en siklosporien is dikwels die eerste keuse vir behandeling, maar die afgelope tyd is daar meer navorsing gedoen oor die gebruik van biologiese terapieë soos TNF-α-remmers. Hierdie biologiese middels word toenemend verkies, veral by pasiënte met ander inflammatoriese toestande, en hulle word vroeër in die siekteproses gebruik.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
